Abdel-Salam Fatma S, Mahmoud Azza A, Ammar Hussein O, Elkheshen Seham A
a Egyptian Patent Office, Academy of Research and Technology , Cairo , Egypt.
b Department of Pharmaceutical Technology , National Research Center , Dokki , Cairo , Egypt.
J Liposome Res. 2017 Mar;27(1):41-55. doi: 10.3109/08982104.2016.1149866. Epub 2016 Mar 9.
CONTEXT: Topical treatment of skin disease needs to be strategic to ensure high drug concentration in the skin with minimum systemic absorption. OBJECTIVE: The aim of this study was to produce semisolid nanostructured lipid carrier (NLC) formulations, for topical delivery of the corticosteroid drug, diflucortolone valerate (DFV), with minimum systemic absorption. METHOD: NLC formulations were developed using a high shear homogenization combined with sonication, using Precirol® ATO5 or Tristearin® as the solid lipid, Capryol™ or isopropyl myristate as the liquid lipid and Poloxamer® 407 as surfactant. The present study addresses the influence of different formulations composition as solid lipid, liquid lipid types and concentrations on the physicochemical properties and drug release profile from NLCs. RESULTS AND DISCUSSION: DFV-loaded NLC formulations possessed average particle size ranging from 160.40 nm to 743.7 nm with narrow polydispersity index. The encapsulation efficiency was improved by adding the lipid-based surfactants (Labrasol® and Labrafil® M1944CS) to reach 68%. The drug release from the investigated NLC formulations showed a prolonged release up to 12 h. The dermatopharmacokinetic study revealed an improvement in drug deposition in the skin with the optimized DFV-loaded NLC formulation, in contrast to a commercial formulation. CONCLUSION: NLC provides a promising nanocarrier system that work as reservoir for targeting topical delivery of DFV.
背景:皮肤病的局部治疗需要讲究策略,以确保皮肤中药物浓度高且全身吸收最少。 目的:本研究的目的是制备半固体纳米结构脂质载体(NLC)制剂,用于局部递送皮质类固醇药物戊酸倍他米松(DFV),使全身吸收最少。 方法:采用高剪切均质结合超声处理来开发NLC制剂,使用Precirol® ATO5或Tristearin®作为固体脂质,Capryol™或肉豆蔻酸异丙酯作为液体脂质,泊洛沙姆® 407作为表面活性剂。本研究探讨了不同制剂组成,如固体脂质、液体脂质类型和浓度对NLCs理化性质和药物释放曲线的影响。 结果与讨论:载有DFV的NLC制剂的平均粒径在160.40nm至743.7nm之间,多分散指数窄。通过添加基于脂质的表面活性剂(Labrasol®和Labrafil® M1944CS),包封率提高到68%。所研究的NLC制剂的药物释放显示出长达12小时的缓释。皮肤药代动力学研究表明,与市售制剂相比,优化的载有DFV的NLC制剂可改善药物在皮肤中的沉积。 结论:NLC提供了一种有前景的纳米载体系统,可作为靶向局部递送DFV的储库。
Int J Nanomedicine. 2016-10-5
Int J Nanomedicine. 2019-10-25
Nanotechnology. 2010-12-20